New drug PHST001 enters first human tests for hard-to-treat cancers
NCT ID NCT06840886
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This early-phase study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if it can shrink tumors. About 272 people with cancers like ovarian, endometrial, bile duct, or brain tumors will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Duke Cancer Institute
RECRUITINGDurham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Mount Sinai
NOT_YET_RECRUITINGNew York, New York, 10029, United States
-
NEXT Oncology - Dallas
RECRUITINGIrving, Texas, 75039, United States
-
NEXT Oncology - Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Precision NextGen Oncology & Research Center
NOT_YET_RECRUITINGBeverly Hills, California, 90212, United States
-
START Center for Cancer Research - Long Island New York
RECRUITINGLake Success, New York, 11042, United States
-
START Center for Cancer Research - Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Center for Cancer Research - Texas
RECRUITINGFort Worth, Texas, 76104, United States
-
Sarah Cannon Research Institute (SCRI) Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
RECRUITINGDenver, Colorado, 80218, United States
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
-
Stanford University School of Medicine
RECRUITINGPalo Alto, California, 94304, United States
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
-
University of Michigan Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Texas (UT) Health
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37203, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.